Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22 CAR T-cells for B-ALL Following CD19 CAR T-cell Therapy
NCT07328503Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2026
- Primary completion
- Jan 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD22-CAR-T in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Started Jun 2026; status: recruiting.
02
Drugs
CD22-CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07328503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328503.